--- title: Alzheimer’s Biomarker Platform | p-Tau217, BD-Tau & Chemiluminescence description: "AD research: Vazyme chemiluminescence platform—500 fg/mL, 120 tests/h, 8 species/models, BD-Tau, p-Tau217/181, Aβ1-40/42, GFAP, NfL. For research use only." --- [Skip to content](https://info.vazymeglobal.com/alzheimer-biomarkers#ad-main) [![Vazyme](https://info.vazymeglobal.com/hubfs/raw_assets/public/Vazyme_AD_Biomarker_Flexible_v1/images/vazyme-logo.png)](https://www.vazymeglobal.com/) [Highlights](https://info.vazymeglobal.com/alzheimer-biomarkers#performance)[Applications](https://info.vazymeglobal.com/alzheimer-biomarkers#markers)[Core Panel](https://info.vazymeglobal.com/alzheimer-biomarkers#panel)[About Vazyme](https://info.vazymeglobal.com/alzheimer-biomarkers#about) # One Platform *Expandable Alzheimer's Biomarkers* Amyloid deposition and Tau phosphorylation can begin 10–20 years before cognitive symptoms emerge. Built on Vazyme's chemiluminescence platform, our solution combines novel biomarkers, cross-species applicability, ultrasensitive detection, and high-throughput testing to deliver reproducible data for AD research. [Request an Online Demo](https://info.vazymeglobal.com/alzheimer-biomarkers#demoForm)[Explore Performance Data](https://info.vazymeglobal.com/alzheimer-biomarkers#performance) Looking for method validation first? [View concordance with Supplier S →](https://info.vazymeglobal.com/alzheimer-biomarkers#panel) ![Elf-S290(正)6-5](https://info.vazymeglobal.com/hubfs/Elf-S290(%E6%AD%A3)6-5.png) Why Now ### Pathology Begins Before Symptoms In Alzheimer's disease, amyloid deposition and Tau phosphorylation can progress for years before cognitive symptoms emerge. The earlier these changes are quantified, the wider the window for intervention. The Challenge ### Early Signals at Extremely Low Concentrations Early pathology-related proteins in blood can be present at fg/mL levels. Conventional methods may not detect these low-abundance targets reliably, creating a need for ultrasensitive assays. The Opportunity ### Fluid Samples: Accessible & Longitudinal Compared with PET and lumbar puncture, blood sampling is less invasive, more accessible, and generally less costly—making it well suited to large-cohort research screening and longitudinal follow-up. ![0920AD配图(3)(1)-3](https://info.vazymeglobal.com/hubfs/0920AD%E9%85%8D%E5%9B%BE(3)(1)-3.jpg) 1 **High-Throughput Automation** Free researchers from repetitive manual steps so they can focus on the data. 2 **Expandable Biomarker Menu** 18 validated assays and 40+ in the pipeline, featuring an expandable menu covering emerging AD biomarkers to grow with your research. 3 **Cross-Species Research Support** One biomarker matrix covers humans, mice, non-human primates, pigs, and brain organoids. Switch models without changing platforms. ## Low-Abundance Signals? Large Cross-Species Cohorts? Early blood-based signals can be as low as fg/mL, while large-cohort studies often span multiple species and sample types. Address your challenges on a single platform. 500 fg/mL ### Ultra-Sensitive: Catches Low-Abundance Signals Detection sensitivity down to 500 fg/mL. Compatible with EDTA plasma, cerebrospinal fluid, brain tissue lysate, and brain organoid culture supernatant. 240 tests/h ### High Throughput: Built for Large Cohorts Throughput: 240 tests/h. Sample volume: 50–100 µL. Within-run precision: CV ≤ 8%. 8 species & model types ### Cross-Species: One Matrix Covers All Validated sample-type combinations cover humans, WT / 5×FAD / P301S mice, two macaque species, pigs, and brain organoids. BD-Tau ### New Target: Brain-Derived Tau Specifically identifies and quantifies CNS-derived total and phosphorylated tau without peripheral interference to deliver a truer read of brain pathology. ## More Biomarkers. The Right Panel for Your Study From amyloid pathology to genetic risk, four biomarker families cover core needs in AD research and can be flexibly combined by study design and research stage. ### Amyloid / Neuronal Injury / Neuroinflammation Core biomarkers covering amyloid pathology, axonal injury, and glial activation. Aβ1-40Aβ1-42NfLGFAPUCH-L1 ### Full-Spectrum Tau Biomarkers Total Tau and multiple phosphorylation sites support research across different classification and staging needs. T-Taup-Tau181p-Tau217p-Tau205p-Tau231np-Tau217 ### Brain-Derived Tau (BD-Tau) Specifically recognize brain-derived Tau while avoiding interference from peripheral signals—a core differentiator of this solution. BD-Taup-BD-Tau217p-BD-Tau181p-BD-Tau231p-BD-Tau205np-BD-Tau217 ### Genetic Risk Biomarker Add the dimension of genetic susceptibility to support risk stratification and population-cohort study design. ApoE4 ## Brain-Derived Tau (BD-Tau): A Clearer View of Tau Signals from the Brain Not all plasma tau comes from the brain. Research shows that roughly 80% of plasma total tau (T-Tau) originates in peripheral tissues with only about 20% being brain-derived. Diluted by peripheral abundance, plasma T-Tau alone gives an unclear picture of neuronal injury and neurodegeneration. **From Measuring Total Tau to Isolating the Brain-Derived Signal** Vazyme BD-Tau assays specifically detect brain-derived Tau and phosphorylated brain-derived Tau, helping differentiate the target signal from peripheral Tau within the complex plasma matrix. p-Tau217 tracks closely with brain tau pathology, making it a high-value blood biomarker for AD research. Yet its extremely low plasma abundance and susceptibility to matrix interference place exceptional demands on assay sensitivity and specificity. Conventional platforms often struggle to reliably detect these faint signals in early AD samples. **From Detecting Tau Fragments to Specifically Detecting p-Tau217** With highly specific antibody pairs and an ultrasensitive chemiluminescence platform, the Vazyme p-Tau217 assay specifically recognizes p-Tau217, reduces plasma-matrix interference, and reliably detects low-abundance p-Tau217 in plasma—supporting research into early AD screening, pathological staging, and study evaluation. ## Phosphorylated Tau217 (p-Tau217): Make Low-Abundance, Specific Signals Reliably Visible ## Six Core AD Biomarkers. One Panel, Strong Concordance Cover key biomarkers in AD research while balancing multiplex efficiency with result consistency. [![AD实验数据图.png](https://info.vazymeglobal.com/hubfs/AD%E5%AE%9E%E9%AA%8C%E6%95%B0%E6%8D%AE%E5%9B%BE.png.jpg)](https://info.vazymeglobal.com/hubfs/AD%E5%AE%9E%E9%AA%8C%E6%95%B0%E6%8D%AE%E5%9B%BE.png.jpg) ### Concordance with the Supplier S Platform All six core biomarkers achieved linear correlations of R² ≥ 0.94 Aβ1-40**R² 0.9518** Aβ1-42**R² 0.9538** p-Tau181**R² 0.9400** p-Tau217**R² 0.9642** NfL**R² 0.9528** GFAP**R² 0.9433** **Core Biomarkers** Aβ1-40 · Aβ1-42 · p-Tau181 · p-Tau217 · GFAP · NfL **Compatible Samples** EDTA plasma · cerebrospinal fluid · brain tissue lysate · brain organoid culture supernatant **Applicable Species** human · mouse · NHP · pig **Research Continuity** Supports continuity from preclinical and translational studies to clinical research. ## Peer-Reviewed Research Advancing the AD Field From exploratory studies to publication, Vazyme empowers research teams with **high accuracy** and **robust stability**, helping them address scientific challenges and advance AD research. ***Alzheimer's & Dementia*** Implementing plasma p-tau217 and cognitive testing for Alzheimer's screening in low-education populations in central China 2026.02 Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China 2025.09 Retinal microvascular alterations in Alzheimer's disease: Linking blood plasma biomarkers and cerebral small vessel pathology 2025.08 ***Alzheimer's Research & Therapy*** Age-dependent diagnostic and correlational architecture of multiple plasma biomarkers in Alzheimer's disease: a cross-ethnic, cross-platform validation study 2026.06 Performance of Plasma pTau217, pTau181 and Their Ratios to Aβ42 in Detecting Aβ Pathology Using a China-Developed Direct Chemiluminescence Assay 2026.04 ## Biomarker Development That Keeps Pace with Your Research Vazyme customizes assay panels around your research objectives, supporting the complete workflow from target design and method validation to reagent delivery with flexible technical support. 60,000+ Sample tests completed Validation tests 18 Biomarkers Developed, Including p-Tau217, BD-Tau, and p-BD-Tau217 Biomarkers developed 40+ In development or planned, including MTBR-Tau243, α-syn, o-α-syn, and α-syn Ser129P In pipeline 4+ Disease areas, including AD, PD, ALS, and autoimmune diseases, with custom development available Disease areas ## One Platform Across Species and Models Match Assays to Your Research Model Swipe horizontally to view all columns → | Biomarker | Human | WT Mouse | 5×FAD Mouse | P301S Mouse | Macaca Mulatta | Macaca fascicularis | Pig | Brain Organoid | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Aβ1-40 | P / CSF | - | P / CSF / BH | - | P / CSF / BH | P / CSF / BH | P / CSF / BH | Culture supernatant | | Aβ1-42 | P / CSF | - | P / CSF / BH | - | P / CSF / BH | P / CSF / BH | P / CSF / BH | Culture supernatant | | p-Tau181 | P / CSF | - | - | P / CSF / BH | P / CSF / BH | P / CSF / BH | - | Culture supernatant | | p-Tau217 | P / CSF | - | - | P / CSF / BH | - | - | - | Culture supernatant | | GFAP | P / CSF | P / CSF / BH | P / CSF / BH | P / CSF / BH | - | - | P / CSF / BH | Culture supernatant | | NfL | P / CSF | P / CSF / BH | P / CSF / BH | P / CSF / BH | P / CSF / BH | P / CSF / BH | P / CSF / BH | Culture supernatant | | BD-Tau | P / CSF | - | - | P / CSF / BH | P / CSF / BH | P / CSF / BH | - | Culture supernatant | | T-Tau | P / CSF | - | - | P / CSF / BH | - | - | - | Culture supernatant | | np-Tau217 | P / CSF | - | - | P / CSF / BH | - | - | - | Culture supernatant | | p-BD-Tau181 | P / CSF | P / CSF / BH | P / CSF / BH | P / CSF / BH | P / CSF / BH | P / CSF / BH | - | Culture supernatant | | p-BD-Tau217 | P / CSF | P / CSF / BH | P / CSF / BH | P / CSF / BH | P / CSF / BH | P / CSF / BH | - | Culture supernatant | | p-Tau231 | P / CSF | - | - | - | - | - | - | - | | p-BD-Tau231 | P / CSF | - | - | - | - | - | - | - | | p-Tau205 | P / CSF | - | - | - | - | - | - | - | | p-BD-Tau205 | P / CSF | - | - | - | - | - | - | - | | np-BD-Tau217 | P / CSF | - | - | - | - | - | - | - | | UCH-L1 (PGP9.5) | P / CSF | - | - | - | - | - | - | - | | ApoE4 | P / CSF | - | - | - | - | - | - | - | `WT` wild type　`P` EDTA plasma　`CSF` cerebrospinal fluid　`BH` brain tissue lysate　`BD` brain-derived. `-` are still under validation , contact us for a feasibility assessment of specific species–sample pairs. ## Advancing Life Science and Human Health Through Innovation Vazyme continuously transforms innovative technologies into products and solutions that serve life science and human health. In Alzheimer's disease research, we focus on biomarker detection and application by leveraging our chemiluminescence platform. Through earlier and more precise detection, we empower researchers to advance AD science. ## Discuss Your Research Needs with Our Technical Experts Tell us about your sample type. We'll start with your study needs and help identify a more suitable approach. 1 Share your requirements (about 1 minute) 2 An application specialist will contact you within 1 business day to confirm technical details 3 Receive technical materials, sample testing, or an online demo as needed We will not share your information with third parties · We typically respond within 1 business day [Request a Demo](https://info.vazymeglobal.com/alzheimer-biomarkers#demoForm)